Net loss of $3.9M for second quarter includes one-time charge for workforce reduction Future operating expenses reduced through workforce and targeted cost reductions Quarterly dividend declared of $0.50 per share First MINI Z™ Handheld Z Backscatter® Screening systems shipped to customers
BILLERICA, Mass., Nov.
-Halozyme completes corporate strategy review and affirms priority focus on advancing PEGPH20 and ENHANZE™- -New patient enrollment underway in Study 202 with 25 patients enrolled and more than 40 clinical sites with IRB approval-
-Royalty revenues of $2.9M, up 71% from the prior quarter- -Launch of HYQVIA® underway in the U.S.- -Second target disclosed in Pfizer collaboration- SAN DIEGO , Nov.
Total net revenues of $25.8 million for the three months ended September 30, 2014 Access rights renewal revenues were $16.8 million, up from $16.1 million in Q214 GAAP operating loss of $0.8 million, adjusted EBITDA of $4.1 million GAAP diluted EPS of breakeven; non-GAAP diluted EPS of $0.18 Generated $3.2 million in free cash flow Cash and cash equivalents of $75.2 million and no debt as of September 30, 2014
WEST PALM BEACH, Fla.
Sign-up for SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015 -- SLXP investment picks
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.